Previous 10 | Next 10 |
NovaBay ® Pharmaceuticals, Inc. (NYSE American: NBY), a pharmaceutical company developing and commercializing high-quality, scientifically formulated eyecare and skincare products, announces that management will present at the Ladenburg Thalmann 2022 Healthcare Conf...
NEW YORK, Sept. 16, 2022 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced that the presentations from the September Life Sciences Virtual Investor Conference are now available for on-demand viewing. REGISTER NOW OR...
NovaBay ® Pharmaceuticals, Inc . (NYSE American: NBY), a pharmaceutical company developing and commercializing high-quality, scientifically formulated eyecare and skincare products, announces that management will present at the Virtual Life Sciences Investor Forum on Th...
NEW YORK, Sept. 12, 2022 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the agenda for the upcoming Life Sciences Virtual Investor Conference to be held on September 15 th . Individual investors, institutional ...
Calm Cool + Corrected Eczema + Dermatitis Clinical Repair Balm to be Featured on “Girls’ Night In with Courtney & Jane” on September 13 at 9 p.m. Eastern Time NovaBay ® Pharmaceuticals, Inc . (NYSE American: NBY), a company developing an...
NovaBay Pharma ( NYSE: NBY ) said on Friday it had entered into a securities purchase agreement with certain institutional investors for a private placement of 3,250 shares of a newly created Series C Non-Voting Convertible Preferred Stock at a price of $1,000 per share. T...
NovaBay ® Pharmaceuticals, Inc. (NYSE American: NBY) (“NovaBay” or the “Company”) announces it has entered into a Securities Purchase Agreement with certain institutional investors in connection with a private placement of 3,250 shares of a newly cre...
NovaBay Pharmaceuticals, Inc. (NBY) Q2 2022 Earnings Conference Call August 11, 2022, 04:30 PM ET Company Participants Jody Cain - LHA Investor Relations Justin Hall - Chief Executive Officer and General Counsel Andy Jones - Chief Financial Officer Kim Sharts...
NovaBay press release ( NYSE: NBY ): Q2 GAAP EPS of -$0.04 in-line. Revenue of $3.04M (+42.7% Y/Y) misses by $0.47M . For further details see: NovaBay GAAP EPS of -$0.04 in-line, revenue of $3.04M misses by $0.47M
Product revenue increased by 43% year-over-year, fueled by a growing product portfolio in the eyecare and skincare markets Continued year-over-year growth in online Avenova ® Spray unit sales Launched seven new OTC Avenova and DERMAdoctor ® products...
News, Short Squeeze, Breakout and More Instantly...
NovaBay Pharmaceuticals Inc. Company Name:
NBY Stock Symbol:
NYSE Market:
NovaBay Pharmaceuticals Inc. Website:
NovaBay ® Pharmaceuticals, Inc . (NYSE American: NBY) announces that it will report financial results for the three and six months ended June 30, 2024 after market close on Tuesday, August 13, 2024 and will hold an investment community conference call that day beginning at 4:30 p.m. Ea...
NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) reports record sales of Avenova ® -branded eyecare products during the Amazon Prime Day event, which was held July 16-17, 2024. Over the two-day period, Avenova sales were 17% higher compared with Prime Day 2023 and were up 40% over ...
NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) (the “Company” or “NovaBay”) today announced the closing of its previously announced underwritten public offering of common stock, pre-funded warrants, Series F-1 warrants, Series F-2 warrants and Series F-3 warrants f...